NPS Downsizes, Seeks Partners To Develop Preos And Teduglutide
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm will reduce its workforce to 35 and focus on outsourcing and partnering to bring the two Phase III compounds to market.